These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Erlotinib: as maintenance monotherapy in non-small-cell lung cancer. Muir VJ; Dhillon S BioDrugs; 2011 Jun; 25(3):139-46. PubMed ID: 21513367 [TBL] [Abstract][Full Text] [Related]
23. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer. Hotta K; Kiura K Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322 [TBL] [Abstract][Full Text] [Related]
24. Comparison is beyond IPASS and OPTIMAL. Lam KC; Mok TS Hong Kong Med J; 2014 Jun; 20(3):176-7. PubMed ID: 24914076 [No Abstract] [Full Text] [Related]
25. Erlotinib: optimizing therapy with predictors of response? Goodin S Clin Cancer Res; 2006 May; 12(10):2961-3. PubMed ID: 16707589 [No Abstract] [Full Text] [Related]
26. Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer. Spitaleri G; Delmonte A; Toffalorio F; De Pas TM; Gregorc V J Thorac Oncol; 2010 May; 5(5):752-4. PubMed ID: 20421772 [No Abstract] [Full Text] [Related]
27. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies]. Pérol M Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154 [No Abstract] [Full Text] [Related]
28. [Erlotinib in non-small cell lung cancer: experience of clinical hospital for lung diseases Jordanovac]. Plestina S; Samarzija M; Plestina S; Chalfe N; Zuljević E Lijec Vjesn; 2007 Dec; 129(12):387-90. PubMed ID: 18383740 [TBL] [Abstract][Full Text] [Related]
29. [Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer]. Lai RS; Xie L; Shen LS; He YM; Zhu CL Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):745-6. PubMed ID: 16536324 [No Abstract] [Full Text] [Related]
30. Clinical experience with erlotinib in non-small-cell lung cancer. Felip E; Rosell R Drugs Today (Barc); 2006 Mar; 42(3):147-56. PubMed ID: 16628257 [TBL] [Abstract][Full Text] [Related]
31. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
32. Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells. Liu D; Yang Y; Zhao S J Formos Med Assoc; 2014 Mar; 113(3):141-2. PubMed ID: 24630031 [No Abstract] [Full Text] [Related]
33. Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer? Jänne PA Am J Respir Crit Care Med; 2008 Oct; 178(8):783-5. PubMed ID: 18832554 [No Abstract] [Full Text] [Related]
34. [Erlotinib in second/third line treatment for non-small cell lung cancer (NSCLC)]. Sárosi V; Balikó Z Orv Hetil; 2007 Aug; 148(32):1525-9. PubMed ID: 17675281 [TBL] [Abstract][Full Text] [Related]
37. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? Cappuzzo F J Natl Cancer Inst; 2005 Jun; 97(12):868-9. PubMed ID: 15956643 [No Abstract] [Full Text] [Related]
38. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271 [TBL] [Abstract][Full Text] [Related]